Spotlight's proprietary targeted active gene editor (TAGE) technology platform develops programmable CRISPR ribonucleoproteins optimized for in vivo cell-targeted delivery. The company's approach avoids complexities and toxicities associated with cell, viral, and nanoparticle-based delivery methods. Lead candidates include those targeting hemoglobinopathies and immune-oncology applications.

The series A financing was led by GV, formerly Google Ventures.